Sanofi
SNYHealthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was 7.05% in Q3 FY26, the highest of these four quarters.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | 10.9% | 0.0% | 5.9% | 0.0% |
| ROIC | 6.6% | 6.1% | 6.6% | 7.0% |
Debt
Net debt is 2.76× a year’s EBITDA. Debt is 0.24× equity, against 0.31× in Q2 FY26.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Debt / equity | 0.3× | 0.2× | 0.3× | 0.2× |
| Net debt / EBITDA | 11.0× | 6.1× | 7.1× | 2.8× |
Cash cycle, in days
Customers pay in 2 days, inventory is held 670 days and suppliers are paid in 657. Cash is tied up for 15 days between paying for goods and being paid.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Cash cycle | 149 | 26 | 177 | 15 |
| Days to pay suppliers | 206 | 630 | 196 | 657 |
| Days to be paid | 69 | 4 | 69 | 2 |
Per share, from Q4 FY25
Since Q4 FY25, per share: free cash flow has grown 30.0%; revenue has grown 13.7%; book value has grown 5.67%.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Free cash flow | 1.0× | 0.0× | 0.8× | 1.3× |
| Revenue | 1.0× | 1.1× | 1.1× | 1.1× |
| Book value | 1.0× | 1.1× | 1.0× | 1.1× |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
13.46 | 13.46 | 22.34 | 20.41 |
P/S ratio |
2.24 | 2.12 | 1.79 | 1.67 | |
P/FCF ratio |
6.36 | 6.24 | 7.02 | 5.91 | |
P/Operating CF |
9.73 | 9.54 | 18.91 | 22.48 | |
P/B ratio |
1.46 | 1.43 | 1.26 | 1.22 | |
Price to Tangible BV |
25.20 | 422.81 | 70.02 | 32.46 | |
EV/Sales |
2.47 | 2.39 | 2.11 | 1.91 | |
EV/EBITDA |
13.29 | 13.31 | 11.54 | 10.19 | |
EV/Operating CF |
5.02 | 5.03 | 5.55 | 4.74 | |
EV/FCF |
7.02 | 7.03 | 8.25 | 6.74 | |
Quick Ratio |
0.58 | 0.20 | 0.49 | 0.21 | |
Current Ratio |
1.09 | 1.01 | 0.99 | 1.12 | |
Net Debt/EBITDA |
10.99 | 6.08 | 7.13 | 2.76 | |
Debt/Assets |
14.66% | 14.23% | 16.79% | 13.77% | |
Debt/Equity |
0.26 | 0.25 | 0.31 | 0.25 | |
Asset Turnover |
0.37 | 0.38 | 0.39 | 0.39 | |
Operating CF/Net income |
(13.83) | 0.00 | 13.54 | 1.27 | |
Capex/Depreciation |
(0.47) | — | (0.30) | — | |
Interest Coverage |
(54.17) | 11.72 | 7.49 | 19.58 | |
Research and Development Expense of Revenue |
18.84% | 15.54% | 18.15% | 12.14% | |
Selling, General and Administrative Expense of Revenue |
22.59% | 20.70% | 20.04% | 15.16% | |
Intangible Assets out of Total Assets |
0.53 | 0.54 | 0.53 | 0.52 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.23) | (0.25) | (0.32) | (0.28) | |
Graham Number |
51.89 | 0.00 | 38.11 | 0.00 | |
Earnings Yield |
7.43% | 7.43% | 4.48% | 4.90% | |
Free Cash Flow Yield |
15.73% | 16.04% | 14.24% | 16.92% | |
Revenue per Share |
5.78 | 5.46 | 5.98 | 7.31 | |
Operating CF per Share |
4.98 | 0.00 | 2.26 | 1.83 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
4.98 | 0.00 | 2.26 | 1.83 | |
Cash per Share |
3.55 | 2.69 | 3.09 | 2.86 | |
Shareholders Equity per Share |
33.24 | 35.55 | 33.80 | 35.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
33.24 | 35.55 | 33.80 | 35.13 | |
Free Cash Flow |
12,162.55 | — | 5,398.42 | 4,401.20 | |
Working Capital |
2,949.56 | 182.59 | (474.38) | 3,959.44 | |
Capital Expenditures |
(3,044.60) | — | (1,013.87) | — | |
Net Current Asset Value |
(27,315.39) | (28,928.77) | (32,521.88) | (27,438.69) | |
EV/EBIT |
13.29 | 13.31 | 11.54 | 10.19 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
12.03 | 11.81 | 9.83 | 8.94 | |
| Other line items | |||||
Average Receivables |
9,527.48 | 517.52 | 10,010.20 | 478.08 | |
Average Payables |
8,249.59 | 24,674.95 | 8,172.42 | 26,988.15 | |
Average Inventory |
10,880.71 | 25,263.44 | 11,927.86 | 28,720.35 | |
Average Assets |
143,583.95 | 144,393.75 | 145,955.80 | 150,838.25 | |
Average Common Equity |
80,802.47 | — | 79,748.01 | — |